UnknownPhase 4

GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients

Lead sponsor

Hadassah Medical Organization

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

124

Study population

Type 1 diabetes

Eligibility highlights

•HbA1c ≥8%

Primary endpoint

•HbA1c, change

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01592279

Org study ID597-11

Timeline

Milestones

Study first posted2012-05-07estimated

Last update posted2012-05-07estimated

Study start2012-06 (month precision)

Primary completion2014-06estimated (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Type 1 diabetes

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

1. HbA1C ≥ 8 at screening and at qualification

2. Not treated with GLP-1 analogue

Exclusion criteria

1. Moderate and sever hypoglycemia

2. Creatinin > 2

3. amylase or lipase > 3xULN

4. Calcitonin > 10 pg/ml or Stimulated Calcitonin > 50 pg/ml in women or 80 pg/ml in men

5. ALT or AST > 3X ULN

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint

The primary end point is the change in HbA1C relative to baseline after 3 months treatment with liraglutide in uncontrolled type 1 diabetic patients. The expected change is 1% reduction from baseline.

Time frame:the change in HbA1C relative to baseline after 3 months treatment with liraglutide in uncontrolled type 1 diabetic patients.

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Endogenous insulin secretion and residual β-cell function estimated by the value of C-peptide

Time frame:the change in C-peptide relative to baseline after 3 months treatment with liraglutide in uncontrolled type 1 diabetic patients

C-peptide AUC

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.